

# ICH E2D (R1) EWG Work Plan

## October 12, 2023

**Topic Adoption date:** *November 2019*

**Rapporteur:** *Ms. Vicki Edwards, EFPIA*

**Regulatory Chair:** *Dr. Robert Ball, FDA, United States*

**Last Face-to-Face Meeting:** *Vancouver, Canada, June 2023*

### 1. Key milestones

#### 1.a. Current status of key milestones

Past completion date	Milestone
<i>Jun. 2019</i>	<i>Topic endorsed by ICH Assembly</i>
<i>Sep. 2019</i>	<i>ICH approval to form Informal Working Group</i>
<i>Nov. 2019</i>	<i>Endorsement of formal EWG by ICH Management Committee</i>
<i>Nov. 2019</i>	<i>Concept Paper Endorsement by ICH Management Committee</i>
<i>Nov. 2019</i>	<i>Business Plan Endorsement by ICH Management Committee</i>
<i>Jul. 2023</i>	<i>Plenary Working Party (PWP) Consultation</i>

#### 1.b. Future anticipated key milestones

Expected future completion date	Milestone
<i>Jan. 2024</i>	<i>Step 1 Experts sign off</i>
<i>Feb. 2024</i>	<i>Step 2a Endorsement by Members of the Assembly/Step 2b Endorsement by Regulatory Members of the Assembly. Release for public consultation</i>
<i>Jul.2024</i>	<i>Step 3 Regulatory Consultation and Discussion</i>
<i>Jan. 2025</i>	<i>Plenary Working Party (PWP) Consultation</i>
<i>Apr. 2025</i>	<i>Step 3 Regulatory Experts sign off</i>
<i>May. 2025</i>	<i>Step 4 Adoption of ICH Harmonized Guideline by Regulatory Members of the Assembly</i>

## 2. Timeline for specific tasks

<b>Beginning date</b>	<b>End date</b>	<b>Task / Activity</b>	<b>Details</b>
<b>Dec. 2022</b>	<b>Dec. 2023</b>	<i>EWG will meet weekly via tele/web conferences</i>	<i>Weekly EWG meetings extended, and biweekly meetings added as needed to meet timelines</i>
<b>01 Aug. 2023</b>	<b>31 Dec 2023</b>	<i>EWG final amendments to guideline</i>	<i>Final amendments made to guideline based on PWP and stakeholder comments</i>
<b>01 Jan. 2024</b>	<b>15 Jan. 2024</b>	<i>EWG consensus on final guideline</i>	<ol style="list-style-type: none"> <li>1. <i>EWG reaches consensus on the final revised guideline (this will become the Step 1 Technical Document)</i></li> <li>2. <i>Prepare supplementary documentation to support Step 2 public consultation.</i></li> </ol>
<b>16 Jan. 2024</b>	<b>31 Jan. 2024</b>	<i>Step 1 Sign-Off by Topic Leaders of EWG</i>	<i>ICH Secretariat to organize Step 1 Experts Sign-Off by the Topic Leaders of the EWG</i>
<b>01 Feb. 2024</b>	<b>29 Feb. 2024</b>	<i>Step 2a Endorsement by Members of the Assembly/Step 2b Endorsement by Regulatory Members of the Assembly.</i>	
<b>01 Mar. 2024</b>	<b>30 July 2024</b>	<i>Step 3 Regulatory Consultation and Discussion</i>	<i>Released for Public consultation (5 months)</i>
<b>01 Aug. 2024</b>	<b>31 Dec. 2024</b>	<i>EWG Comment Review and Final Amendments to Guideline</i>	<i>Review and adjudicate all comments from public consultation. Prepare final amendments to guideline based on public comments.</i>
<b>01 Jan. 2025</b>	<b>31 Jan. 2025</b>	<i>Plenary Working Party (PWP) Consultation (1 month)</i>	<i>Revised guideline sent to PWP for consultation</i>

<b>01 Feb. 2025</b>	<b>31 Mar. 2025</b>	<i>EWG Final Review and Internal Stakeholder Sign-off. (2 months)</i>	<i>Final amendments made to guideline. EWG reaches consensus on the final revised guideline. Prepares guideline for Step 3 Regulatory Experts sign off.</i>
<b>01 Apr. 2025</b>	<b>30 Apr. 2025</b>	<i>Step 3 Regulatory Experts sign off (1 month)</i>	
<b>01 May 2025</b>	<b>31 May 2025</b>	<i>Step 4 Adoption of ICH Harmonized Guideline by Regulatory Members of the Assembly (1 month)</i>	